Synergistic Integration of HDAC Inhibitors and Individualized Neoantigen Therapy (INT): A Next-Generation Combinatorial Approach for Cancer Immunotherapy
Vaccines · 22.05.2025 · 13 (6) · 550
DOI: 10.3390/vaccines13060550 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 22.05.2025. Verfasst von Rui Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chinese Medicine Oncology, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 171 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Cancer immunotherapy has advanced, yet therapeutic resistance and low response rates remain problematic. This study explores histone deacetylase inhibitors (HDACis) as adjuvants for cancer vaccines to enhance anti-tumor immunity and overcome these challenges.
Methods
A comprehensive review of relevant literature was conducted. Studies on the immunomodulatory mechanisms of HDACis, their effects on Individualized neoantigen therapy (INT), and clinical applications were analyzed.
Results
HDACis enhance anti-tumor immunity through multiple mechanisms. They activate endogenous retroelements, expanding the “antigen repository”. HDACis also upregulate MHC class I and II molecules, enhance the antigen processing machinery, improve MHC—I complex stability, and remodel the tumor immune microenvironment. Early clinical trials of HDACis combined with peptide vaccines show promising safety and immunological responses. However, challenges exist, such as HDACi-mediated PD-L1 regulation, optimal sequencing strategies, and biomarker development.
Conclusions
The combination of HDACis and cancer vaccines has significant potential in cancer immunotherapy. Despite challenges, it offers a new approach to overcome tumor heterogeneity and immune evasion, especially for patients with limited treatment options. Further research on toxicity management, triple-drug combinations, biomarker identification, and delivery systems is needed to fully realize its clinical benefits.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chinese Medicine Oncology, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China.
- Department of Chinese Medicine, Naval Medical University, Shanghai 200433, China.
- Department of Gastroenterology, Tongde Hospital of Zhejiang Province, Hangzhou 310012, China.
ORCID-Profile: Rui Han, Huiling Zhou
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Han, R., Zhou, H., Peng, B., Yu, S., Zhu, J., & Chen, J. (2025). Synergistic Integration of HDAC Inhibitors and Individualized Neoantigen Therapy (INT): A Next-Generation Combinatorial Approach for Cancer Immunotherapy. Vaccines, 13(6), 550. https://doi.org/10.3390/vaccines13060550
Vancouver
Han R, Zhou H, Peng B, Yu S, Zhu J, Chen J. Synergistic Integration of HDAC Inhibitors and Individualized Neoantigen Therapy (INT): A Next-Generation Combinatorial Approach for Cancer Immunotherapy. Vaccines. 2025;13(6):550. doi:10.3390/vaccines13060550
BibTeX
@article{Han2025,
author = {Han, Rui and Zhou, Huiling and Peng, Baoqing and Yu, Shasha and Zhu, Jiajie and Chen, Jiaojiao},
title = {Synergistic Integration of HDAC Inhibitors and Individualized Neoantigen Therapy (INT): A Next-Generation Combinatorial Approach for Cancer Immunotherapy},
journal = {Vaccines},
year = {2025},
volume = {13},
number = {6},
pages = {550},
doi = {10.3390/vaccines13060550}
}
EUVIMED